Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine.

IF 7.2 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2026-07-06 DOI:10.1038/s41541-026-01515-8

Chaitanya Kurhade, Wei Chen, Weiqiang Li, Kristin R Tompkins, Lyndsey T Martinez, Swati Rajput, Emily Babiarz, Aaron Yam, Shin-Ae Lee, Shikha Shrivastava, Sarah O'Leary, Subrata Saha, Hui Yao, Li Hao, Todd Coffey, Carla Iris Cadima Couto, Alexander Muik, Raquel Munoz Moreno, Wesley Swanson, Pilar Mendoza, Uğur Şahin, Annaliesa S Anderson, Kena A Swanson, Pirada Suphaphiphat Allen, Kayvon Modjarrad

引用次数: 0

Abstract

SARS-CoV-2 evolution toward antigenically distinct lineages drives escape from host immunity. JN.1 lineage derivatives have recently dominated the global epidemiologic landscape. In preclinical models, an LP.8.1-adapted BNT162b2 vaccine elicited higher serum neutralizing antibody responses against contemporary, circulating JN.1 sublineages, including the epidemiologically dominant XFG lineage, as compared to JN.1 and KP.2 vaccines. These findings supported the selection of an LP.8.1-adapted vaccine for the composition of the 2025-26 COVID-19 vaccine formula.

查看原文本刊更多论文

lp .8.1适应的BNT162b2 COVID-19疫苗的临床前免疫原性

SARS-CoV-2向抗原性不同谱系的进化驱动逃离宿主免疫。jn1谱系衍生物最近在全球流行病学领域占据主导地位。在临床前模型中，与jn1和KP.2疫苗相比，适应lp .8.1的BNT162b2疫苗对流行的jn1亚谱系（包括流行病学上占优势的XFG谱系）产生了更高的血清中和抗体反应。这些发现支持选择lp .8.1适应疫苗作为2025-26年COVID-19疫苗配方的组成。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.